GFM
DYN icon

GF Fund Management’s Dyne Therapeutics DYN Stock Holding History

GF Fund Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.2K Buy
3,208
+402
+14% +$6.93K ﹤0.01% 380
2025
Q4 		$54.9K Sell
2,806
-255
-8% -$4.83K ﹤0.01% 400
2025
Q3 		$38.7K Buy
3,061
+456
+18% +$5.2K ﹤0.01% 420
2025
Q2 		$24.8K Hold
2,605
– – ﹤0.01% 479
2025
Q1 		$27.2K Buy
2,605
+468
+22% +$6.7K ﹤0.01% 470
2024
Q4 		$50.3K Buy
+2,137
New +$63.2K ﹤0.01% 388

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

GF Fund Management's DYN Position: Q1 2026 in Review

GF Fund Management increased its Dyne Therapeutics (DYN) stake by 14% in Q1 2026, buying an estimated $6.93K and bringing the position to 3,208 shares worth $58.2K. The position accounts for ﹤0.01% of the portfolio, ranked #380.

GF Fund Management first reported a position in DYN in Q4 2024 and has held it in 6 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • GF Fund Management held 3,208 shares of Dyne Therapeutics worth $58.2K as of Q1 2026.
  • GF Fund Management bought 402 Dyne Therapeutics shares in Q1 2026, an estimated $6.93K.
  • Dyne Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #380 holding.
  • GF Fund Management first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.